Akebia Therapeutics (AKBA) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to 0.11.
- Akebia Therapeutics' Equity Ratio rose 14694.05% to 0.11 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.11, marking a year-over-year increase of 14694.05%. This contributed to the annual value of 0.22 for FY2024, which is 7614.78% down from last year.
- Akebia Therapeutics' Equity Ratio amounted to 0.11 in Q3 2025, which was up 14694.05% from 0.08 recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Equity Ratio ranged from a high of 0.34 in Q1 2021 and a low of 3.49 during Q3 2022
- Its 5-year average for Equity Ratio is 0.17, with a median of 0.01 in 2022.
- Per our database at Business Quant, Akebia Therapeutics' Equity Ratio plummeted by 163307.72% in 2022 and then soared by 16555.22% in 2025.
- Over the past 5 years, Akebia Therapeutics' Equity Ratio (Quarter) stood at 0.14 in 2021, then plummeted by 89.49% to 0.01 in 2022, then plummeted by 961.44% to 0.13 in 2023, then crashed by 76.15% to 0.22 in 2024, then surged by 151.24% to 0.11 in 2025.
- Its Equity Ratio was 0.11 in Q3 2025, compared to 0.08 in Q2 2025 and 0.08 in Q1 2025.